Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma announced that Genethon will present preliminary data from a Phase 2 trial of imlifidase as a pre-treatment for gene therapy in patients with severe Crigler-Najjar syndrome at the ESGCT congress. The trial, which aims to address the barrier of anti-AAV antibodies in gene therapy, could significantly impact the treatment landscape for this ultra-rare disease, potentially enabling more patients to benefit from gene therapies.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing innovative treatments for rare immunological conditions. The company’s portfolio includes imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule. Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm.
Average Trading Volume: 503,516
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.81B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.